RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
RECURSION PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.61+0.15 (+4.18%)
Close on Oct 19, 2026
- Market cap
- $1.92B
- P/E (TTM)
- –
- Dividend yield
- –
RECURSION PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating revenue | $53.94M | $65.74M | $74.26M | $43.42M | $64.51M | $59.82M | $58.49M | $64.60M | $48.62M | $45.23M | $43.88M | $46.93M | 98.3% | -16.4% |
| Grant revenue | $917.00K | $670.00K | $425.00K | $274.00K | $82.00K | -$25.00K | $351.00K | $583.00K | $1.01M | $1.00M | $699.00K | $432.00K | 1.7% | +1018.3% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | $39.34M | – | – | – | $57.38M | – | – | – | – | – | – | – |
| United Kingdom | – | – | $35.34M | – | – | – | $1.14M | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Recursion Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.